Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 5/20 | 0.59 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.50 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.50 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.47 |
| ▸ | MME | P08473 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | CPA1 | P15085 | 1/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | PTGES | O14684 | 1/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2744644 | 1.00 | FFAR1 (0.59) | FFAR1CYSLTR2CYSLTR1SLC22A12MME | |
| SCHEMBL2744646 | 1.00 | FFAR1 (0.59) | FFAR1CYSLTR2CYSLTR1SLC22A12MME | |
| SCHEMBL2745152 | 0.87 | L3MBTL1 (0.49) | FFAR1CYSLTR2CYSLTR1SLC22A12MME | |
| SCHEMBL20905595 | 0.86 | MME (0.59) | FFAR1CYSLTR2CYSLTR1MMEACE | |
| SCHEMBL1634517 | 0.85 | PPARA (0.48) | FFAR1SLC22A12MMEACECPA1 | |
| SCHEMBL28560495 | 0.81 | FFAR1 (0.52) | FFAR1CYSLTR2CYSLTR1MMEACE | |
| SCHEMBL957978 | 0.81 | SLC22A12 (0.68) | FFAR1SLC22A12MAOBNR4A2 | |
| SCHEMBL954242 | 0.79 | FFAR1 (0.54) | FFAR1CYSLTR2CYSLTR1SLC22A12 | |
| SCHEMBL12191887 | 0.79 | TAAR1 (0.63) | FFAR1MAOB | |
| SCHEMBL12191881 | 0.79 | TAAR1 (0.63) | FFAR1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203793-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-08-13 | — | — | US | claimed |
| EP-1948152-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2008-07-30 | — | — | EP | claimed |
| WO-2007056771-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-05-18 | — | — | WO | claimed |
| EP-1948152-B1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORP (US) | 2013-01-02 | — | — | EP | disclosed |
| US-8178675-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178675-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178675-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090203793-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090203793-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090203793-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-08-13 | — | — | US | disclosed |
| EP-1948152-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007056771-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203793-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | CPT1B, CPT1A, GOT2 | FFAR1 46/4885CYSLTR2 2869/4885CYSLTR1 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.